Back to Report Store Home

Biosimilars – Regulatory Framework and Pipeline Analysis

  • Published: Jun-2015
  • Report Code: GBI057CBR
  • Report Format: pdf

Description

Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal. Biologic products are complex in structure and follow a complex manufacturing process thus, some variation exists between the reference product and its biosimilar. It is very important to assess the variations in biosimilars by comparing with reference product to ensure quality, non-clinical, and clinical properties, which has given rise to the regulatory requirements for biosimilars. Regulatory requirement for approving biosimilars varies across different regulatory bodies. However, all the countries have derived the basic theme from EMA and WHO guidelines for framing their regulatory structure. There is a need to harmonize the nomenclature of biosimilars, extrapolation of indications, and interchangeability of biosimilars with reference products across the regulatory bodies. Biosimilars market is developing and it could be well established with the pipeline that is poised to deliver a wave of biosimilars in the market in the near future

Scope

  • The scope of the report includes:

  • Introduction

  • Market dynamics: Trends, Drivers, and Barriers

  • WHO guidance for biosimilars

  • Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for:

  • Europe

  • USA

  • India

  • South Korea

  • Japan

  • China

  • Key players

  • Pipeline Analysis

  • Overview

  • By Stage of Development / Molecule / Therapy Area / Indication

  • Late-Stage / Phase II / Phase I Pipeline Biosimilars

Reasons To Buy

  • The report will enhance your decision-making capability by allowing you to:

  • Understand the regulatory requirement and regulatory framework that facilitates effective product development strategy as biosimilars industry is currently highly focused, growing, and outpacing the growth rate of small molecule pharmaceutical market

  • Targeting geographies would be easy by comparing different regulatory frameworks; this would also provide a base for designing a strategy to enter the developed markets. Biosimilars are of interest in developed countries to reduce the healthcare expenditure

  • With the recent approvals of biosimilars by USFDA, the biosimilars market is going to grow and this report examines the post approval market landscape

  • Examine the biosimilars pipeline and specifies the products that are highly targeted, it also includes analysis of highly focused indications, mechanism of actions, and therapy areas in the pipeline

  • Analyze the details of the clinical pipeline that includes late stage products, Phase II, and Phase I products. Detailed understanding of the pipeline will help in targeting the products for development, rate the current products and predict the competition

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$8985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards